Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Feb 1.

Published in final edited form as: J Allergy Clin Immunol. 2017 May 4;141(2):659–670.e2. doi: 10.1016/j.jaci.2017.04.020

Anti-CD25 administration attenuates oral tolerance. (A) Protocol for induction of tolerance to peanut protein and treatment with anti-CD25. Anti-CD25 was administered to pups on days -21, -1, and 20 (B) Kinetics of the development of diarrhea in peanut tolerant mice treated with anti-CD25 or control IgG. (C) Scores based on the severity of clinical signs were assessed 30 minutes after oral challenge. (D) Serum levels of peanut-specific IgE, IgG1, and IgG2a were assessed by ELISA 24 hrs after the last challenge and expressed as optical density of diluted serum. (E) Representative flow cytometric analysis of the percentage of FoxP3-expressing cells among the CD4⁺CD25⁺ T cells from MLN of tolerant mice treated with anti-CD25 or control IgG. (F) Representative flow cytometric analysis of the percentage of CD4⁺CD25⁺ T cells in spleen and peripheral blood from tolerant mice treated with anti-CD25 or control IgG. (G) IFNG, IL10, IL13, IL17A, and TGFβ mRNA expression in jejunum of tolerant mice treated with anti-CD25 or control IgG. (H) T-bet, GATA3, and RORγt expression in jejunum of tolerant mice treated with anti-CD25 or control IgG. Results were obtained from 2 individual experiments with 4 mice per group. *P<0.05, **P<0.01, #P<0.001, n.s. not significant.

Anti-CD25 administration attenuates oral tolerance. (A) Protocol for induction of tolerance to peanut protein and treatment with anti-CD25. Anti-CD25 was administered to pups on days -21, -1, and 20 (B) Kinetics of the development of diarrhea in peanut tolerant mice treated with anti-CD25 or control IgG. (C) Scores based on the severity of clinical signs were assessed 30 minutes after oral challenge. (D) Serum levels of peanut-specific IgE, IgG1, and IgG2a were assessed by ELISA 24 hrs after the last challenge and expressed as optical density of diluted serum. (E) Representative flow cytometric analysis of the percentage of FoxP3-expressing cells among the CD4⁺CD25⁺ T cells from MLN of tolerant mice treated with anti-CD25 or control IgG. (F) Representative flow cytometric analysis of the percentage of CD4⁺CD25⁺ T cells in spleen and peripheral blood from tolerant mice treated with anti-CD25 or control IgG. (G) IFNG, IL10, IL13, IL17A, and TGFβ mRNA expression in jejunum of tolerant mice treated with anti-CD25 or control IgG. (H) T-bet, GATA3, and RORγt expression in jejunum of tolerant mice treated with anti-CD25 or control IgG. Results were obtained from 2 individual experiments with 4 mice per group. *P<0.05, **P<0.01, #P<0.001, n.s. not significant.